Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19
figureposted on 2020-10-22, 08:56 authored by Joseph A. Lasky, Jyotsna Fuloria, Marion E. Morrison, Randall Lanier, Odin Naderer, Tom Brundage, Allen Melemed
The above Summary Slide represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.